reports
Bavarian Nordic afslutter salget af Priority Review Voucher og opjuste...
Bavarian Nordic afslutter salget af Priority Review Voucher og opjusterer de økonomiske forventninger til 2025 KØBENHAVN, Danmark, 31. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har afsluttet salget af sin Priority Review Voucher (PRV). Ved transaktionens afslutning har selskabet modtaget USD 160 mio. kontant. For yderligere informationer om transaktionen henvises til . Fratrukket royaltybetalingen til National Institutes of Health samt transaktionsomkostninger beløber nettoprovenuet sig til DKK 810 mio., der vil blive indregnet som andre driftsindtægter og ...
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher a...
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration of USD 160 million. See for additional information about the PRV sale. After deduction of royalties to the National Institutes of Health and transaction costs, the net proceeds amount to DKK 810 million, which will be recognized as other operating income, and will therefore ...
Konsortium ledet af Nordic Capital og Permira vil fremsætte kontant fr...
Konsortium ledet af Nordic Capital og Permira vil fremsætte kontant frivilligt anbefalet købstilbud vedrørende Bavarian Nordic MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION KØBENHAVN, Danmark, 28. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) (“Bavarian Nordic”) har i dag offentliggjort, at selskabet har indgået en offentliggørelsesaftale med Innosera ApS ("Tilbudsgiver"), et nystiftet selskab kontrolleret af Nordic Capit...
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recomm...
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, July 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) (“Bavarian Nordic”) announced today that it has entered into an announcement agreement with Innosera ApS (the “Offeror”), a newly formed company controlled by Nordic Capital Fund XI1 and funds managed and advised by...
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordic Capital and Permira. Bavarian Nordic A/S can confirm that we have been in discussions with Nordic Capital and Permira regarding a potential takeover offer for Bavarian Nordic A/S by Nordic Capital and Permira. As these discussions are continuing, there can be no certainty as to whether any offer for Bavarian Nordic A/S by Nordic ...
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordic Capital and Permira. Bavarian Nordic A/S can confirm that we have been in discussions with Nordic Capital and Permira regarding a potential takeover offer for Bavarian Nordic A/S by Nordic Capital and Permira. As these discussions are continuing, there can be no certainty as to whether any offer for Bavarian Nordic A/S by Nordic ...
Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunya...
Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunyavaccinen er blevet accepteret til gennemgang af de canadiske lægemiddelmyndigheder KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om markedsføringstilladelse for den virus-lignende partikel (VLP)-baserede, enkelt-dosis chikungunyavaccinekandidat, CHIKV VLP, til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. Dermed starter myndighedernes standardgenne...
Bavarian Nordic Receives Acceptance from Health Canada for Review of t...
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is comp...
Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk...
Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk land Gentagen ordre fra unavngivet europæisk land til styrkelse af det offentlige beredskab.Sammen med andre nylige ordrer fra ikke-europæiske lande har selskabet nu sikret kontrakter for mere end DKK 3.000 mio. i Public Preparedness-forretningen i 2025, og rammer dermed det forventede interval for dette forretningsområde. KØBENHAVN, Danmark, 9. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har modtaget en kontrakt til en værdi på over DKK 200 mio. på levering af MVA-BN® koppe-/mpoxvaccine ti...
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with ...
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country Recurring order from an undisclosed European country to strengthen public preparedness.Combined with other recent orders from non-European countries, the Company has now secured above DKK 3,000 million in contracts in the Public Preparedness business in 2025, thus entering the targeted guidance interval for this business. COPENHAGEN, Denmark, July 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued over DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a...
Bavarian Nordic sælger Priority Review Voucher for USD 160 mio.
Bavarian Nordic sælger Priority Review Voucher for USD 160 mio. KØBENHAVN, Danmark, 18. juni 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået aftale om salg af sin Priority Review Voucher (PRV) for USD 160 mio. kontant. Bavarian Nordic blev tildelt voucheren i februar 2025 i forbindelse med de amerikanske sundhedsmyndigheders godkendelse af chikungunyavaccinen VIMKUNYA™ til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. I henhold til en licensaftale, der blev overdraget til Bavarian Nordic i forbindelse med opkøbet af ...
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 ...
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for prevention of disease caused by chikungunya virus in people 12 years of age and older. Pursuant to a license agreement assumed upon acquisit...
Indberetning af ledende medarbejdere og disses nærtståendes transaktio...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer KØBENHAVN, Danmark, 9. maj 2025 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse, hvilke hermed offentliggøres i overensstemmelse med §19 i Europa Parlamentets og Rådets forordning (EU) nr. 596/2014 samt Kommissionens Gennemførelsesforordning (EU) nr. 2016/523. Transaktionerne vedrør...
Report of transactions of shares and related securities of Bavarian No...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523. The tra...
Bavarian Nordic offentliggør delårsregnskab for første kvartal 2025
Bavarian Nordic offentliggør delårsregnskab for første kvartal 2025 KØBENHAVN, Danmark, 9. maj 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag regnskab samt rapporterede på begivenheder for første kvartal 2025. Omsætningen i de første tre måneder sted med 62% til DKK 1.347 mio., hvilket afspejler en stærk udvikling i både Travel Health og Public Preparedness. Travel Health omsætning steg med 52% til DKK 680 mio. sammenlignet med første kvartal 2024, hvilket primært var drevet af øget efterspørgsel på vacciner mod rabies og flåtbåren hjernebetændelse (TBE).Public Preparedness...
Bavarian Nordic Announces Interim Results for the First Three Months o...
Bavarian Nordic Announces Interim Results for the First Three Months of 2025 COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 52% to DKK 680 million compared to the first quarter of 2024, primarily driven by increased demand for rabies and tick-borne encephalitis (TBE) vaccines.Public...
Bavarian Nordic er blevet tildelt kontraktoptioner fra den amerikanske...
Bavarian Nordic er blevet tildelt kontraktoptioner fra den amerikanske regering til produktion og levering af frysetørret koppe- og mpoxvaccine Værdien af tildelte kontraktoptioner udgør USD 143.6 mio.Sikrer produktion og levering af frysetørret JYNNEOS® til USA i 2026 KØBENHAVN, Danmark, 6. maj 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Biomedical Advanced Research and Development Authority (BARDA), en del af Administration for Strategic Preparedness and Response (ASPR) ved U.S. Department of Health and Human Services (HHS) har udnyttet yderligere optioner til en værdi af...
Bavarian Nordic Awarded Contract Options from the U.S. Government for ...
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines Exercised options total USD 143.6 millionSecures manufacturing and supply of freeze-dried JYNNEOS® to the U.S. in 2026 COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 143.6 mil...
- Jonathan Moreland
DHIL DIAMOND HILL INVESTMENT GROUP
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
SON SONOCO PRODUCTS COMPANY
TRS TRIMAS CORPORATION
TCBI TEXAS CAPITAL BANCSHARES INC.
TBK TRIUMPH BANCORP INC.
SIG SIGNET JEWELERS LIMITED
NBTB NBT BANCORP INC.
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
GNTX GENTEX CORPORATION
CDXS CODEXIS
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
BANC BANC OF CALIFORNIA INCORPORATED
SNWV SANUWAVE HEALTH
MRTN MARTEN TRANSPORT LTD.
WFT.. WEATHERFORD INTERNATIONAL PLC
NHC NATIONAL HEALTHCARE CORP.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MBIN MERCHANTS BANCORP
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
MCFT MASTERCRAFT BOAT HOLDINGS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
AVTR AVANTOR
FNLC INC.
DLHC FIRST BANCORP
TCBX INC (ME)
JMSB DALEIGH HOLDINGS CORP
MEGI THIRD COAST BANCSHARES INC
OBIO JOHN MARSHALL BANCORP INC
CVI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
PHIN ORCHESTRA BIOMED HOLDINGS INC
NBBK CVR ENERGY
DMA INC.
SUNS PHINIA INC
EVM NB BANCORP INC.
GF DESTRA MULTI ALTERNATIVE FUND
ECF SUNRISE REALTY TRUST
EATON VANCE INSD CALIF MUN BD FD
THE NEW GERMANY FUND
INC.
ELLSWORTH FUND LTD
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
CDXS CODEXIS
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
BANC BANC OF CALIFORNIA INCORPORATED
MRTN MARTEN TRANSPORT LTD.
AVTR AVANTOR
TCBX INC.
GLSI THIRD COAST BANCSHARES INC
JMSB GREENWICH LIFESCIENCES INC
NBBK JOHN MARSHALL BANCORP INC
BHRB NB BANCORP INC.
DMA BURKE HERBERT FINANCIAL SERVICES CORP
DESTRA MULTI ALTERNATIVE FUND
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.